HALO: Halozyme Therapeutics, Inc. Company Value to Net Income

Halozyme Therapeutics, Inc. - graphic logo of issuer HALO

Insurmountable patent barriers and costly trials make entry into the drug delivery niche nearly impossible for Halozyme Therapeutics (HALO). The current P/E ratio visualizes this resilience, with the current value equal to 22.40. The business foundation is based on licensing technologies to pharma behemoths, while the royalty collection model ensures rapid profit growth with minimal operating expenses.

Price to Earnings Ratio: Halozyme Therapeutics (HALO) for 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Halozyme Therapeutics, Inc. (HALO)

- share price and expert price forecast:
Summary company analysis:Halozyme - HALO
Flagship merchandise of Halozyme

The non-cyclical nature of Halozyme Therapeutics (HALO) biotech licensing guarantees a stable royalty stream regardless of macroeconomic shocks. The market capitalization-to-net income ratio mathematically reflects the value of this sustainable income. This coefficient measures investment efficiency and the impact of external factors on the issuer's real yield. The trend in the company's average P/E allows for an assessment of the market's recognition of the business and the timely identification of risks regarding overpaying for the asset.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio RVMD (RevMed)|AAPG (Ascentage) - Company Value to Net Income|P/E Multiple CGON (cgoncology.com)|URGN - Price to Earnings Ratio|BCAX: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca Corp (ERAS) - Price to Earnings Ratio|Delcath - Company Value to Net Income|YMAB (Y-mAbs Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Aura Biosciences, Inc. AURA|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV